A new strain of coronavirus discovered in China, known as HKU5-CoV-2, could be only a few mutations away from triggering the next deadly pandemic, say American scientists. The virus was identified by researchers at Washington State University (WSU). The researchers have said that it shares close genetic similarities with Middle East Respiratory Syndrome (MERS)—a highly lethal virus that kills nearly a third of those it infects. The findings have raised serious concern in the global scientific community.

A Close Cousin of MERS

MERS, which emerged in 2012 and has caused sporadic outbreaks primarily in the Arabian Peninsula, is known for its severe respiratory symptoms and high mortality rate. HKU5-CoV-2, the new virus under scrutiny, belongs to the merbecovirus family—a group of viruses that includes MERS. While not yet known to infect humans, scientists warn that a minor genetic mutation could allow it to do so, raising the possibility of another global health emergency similar to COVID-19.

“This virus may be only a small step away from being able to spill over into humans,” said Professor Michael Letko, a virologist at WSU and co-lead author of the study.

What the Study Found

The study focused on how HKU5-CoV-2 interacts with human cells. Originally found in bats, this virus was identified by Chinese scientists from the same lab some speculate may have been linked to the origins of COVID-19. In the new study, WSU researchers examined the virus's ability to bind to human ACE2 receptors—proteins located in the nose, mouth, and throat that serve as entry points for coronaviruses.

Using advanced cryo-electron microscopy, researchers captured detailed images of the virus's spike protein, revealing that key segments of the spike often remain “closed.” This closed structure typically makes infection harder—but not impossible.

The team observed that while human cells generally resist infection from HKU5-CoV-2, the virus could latch onto human ACE2 receptors if specific mutations occur. These mutations could enable the virus to enter human cells more effectively, increasing its potential to cause disease.

Risks from Intermediate Animal Hosts

Another concern is the possibility of the virus mutating in intermediate animal hosts, such as mink or civets, before jumping to humans. Such transmission chains have been seen in other coronavirus outbreaks, including both SARS and MERS. If HKU5-CoV-2 were to infect these animals, it might gain the ability to infect humans more efficiently, scientists warn.

“Viruses that are already this close to MERS in structure and function are definitely worth monitoring,” Letko emphasized.

Lineage 2 and Immediate Threats

Earlier in 2025, researchers in Wuhan reported that one strain of HKU5—Lineage 2—already shows the ability to bind to human ACE2 receptors without further mutation. This suggests that some forms of the virus may already be equipped to infect humans.

Building on that discovery, the WSU team expanded their research to look at the entire merbecovirus family. Their findings indicate that several other strains, not just Lineage 2, may only require minimal changes to become capable of infecting humans.

Vigilance Needed

As the world continues to recover from the COVID-19 pandemic, scientists stress the importance of ongoing surveillance and pre-emptive research into emerging viruses like HKU5-CoV-2. Even if they cannot yet infect humans, understanding their structure and behavior is crucial for early intervention.

"The lesson from COVID-19 is clear—we cannot afford to ignore even small viral threats," Letko concluded.

Jharkhand Education Minister Ramdas Soren remains in critical condition after suffering a severe brain injury following a fall in the bathroom at his residence early Saturday morning.

According to officials, the minister was initially admitted to a hospital in Jamshedpur, where doctors detected a blood clot in his brain. He was later airlifted to a private hospital in Delhi for more advanced treatment.

Health Minister Irfan Ansari confirmed the incident and said that Soren’s condition deteriorated rapidly after the fall. “Ramdas Soren’s health suddenly declined. He suffered a serious brain injury and internal bleeding in the brain. I have been in constant touch with his family and am monitoring the situation closely,” Ansari said.

Airlifted to Delhi for Advanced Care

After initial treatment in Jamshedpur, the decision was made to transfer the minister to Delhi for more specialized care. Former Union Minister and senior BJP leader Arjun Munda, who was present at Sonari Airport during the airlift, said, “I have spoken to the director of Delhi Apollo Hospital, and he has assured that treatment will begin as soon as the minister reaches. The doctors have diagnosed a brain hemorrhage due to a sudden increase in pressure. His condition is critical, but we are hopeful.”

On Saturday evening, the Delhi hospital issued a statement confirming that the minister was on life support and under the care of a multidisciplinary team of senior specialists. “A close watch is being kept on all vital parameters,” a spokesperson for the hospital said.

Understanding Brain Hemorrhage: What Happened to Ramdas Soren?

A brain hemorrhage, commonly known as a brain bleed, occurs when there is bleeding either inside the brain tissue or in the space between the brain and the skull. It is a medical emergency that can cause damage by increasing pressure on the brain, reducing oxygen supply, and killing brain cells.

Doctors categorize brain hemorrhages based on where the bleeding occurs:

Bleeding Outside Brain Tissue (Within Skull)

Epidural Hemorrhage: Occurs between the skull and the outer membrane (dura mater)

Subdural Hemorrhage: Bleeding between the dura mater and the arachnoid membrane

Subarachnoid Hemorrhage: Bleeding between the arachnoid and the innermost membrane (pia mater)

Bleeding Inside Brain Tissue

Intracerebral Hemorrhage: Bleeding within the brain’s tissues

Intraventricular Hemorrhage: Bleeding into the brain’s internal cavities that hold cerebrospinal fluid

In Soren’s case, doctors suspect a form of intracerebral or subdural hemorrhage, given the mention of clotting and pressure build-up.

Symptoms and Risks

Brain bleeds can come on suddenly and include symptoms like severe headache, nausea, vomiting, confusion, weakness or numbness (especially on one side of the body), vision problems, dizziness, seizures, slurred speech, and even coma. A particular warning sign is the so-called “thunderclap headache”, a sudden, intense pain that can signal a subarachnoid hemorrhage.

When not treated immediately, such bleeds can be fatal or lead to long-term neurological complications. In some cases, surgery is required to relieve pressure and remove clots.

What’s Next?

As of Saturday night, Ramdas Soren continues to remain on life support. No additional medical bulletins have been released since his transfer to Delhi, but officials have indicated that his condition is still being evaluated. “We are hoping for positive progress, but his condition remains critical,” said Arjun Munda.

Family members and close colleagues are at the hospital, and the Jharkhand government has said it will provide all necessary support for his treatment.

The political and public community has expressed concern and extended wishes for the minister’s speedy recovery. Further updates are awaited from the hospital and health authorities.

In a growing food safety alert, the U.S. Food and Drug Administration (FDA) has escalated a butter recall to a Class II risk level following concerns over undeclared allergens. The product in question, European Style Butter Blend manufactured by Bunge North America Inc., was found to contain milk that was not listed on the packaging label.

Class II Recall Indicates Moderate Health Risk

The risk reclassification, issued on Wednesday, July 30, places the product under the FDA’s second-highest warning level. According to the FDA, a Class II recall involves “a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.”

While no illnesses or allergic reactions have been reported so far, the undeclared presence of milk poses a potential health hazard to people with dairy allergies or lactose intolerance.

Initial Voluntary Recall Announced in Mid-July

The recall began as a voluntary measure by Bunge on July 14, when the company announced it was pulling approximately 64,800 pounds, or 1,800 cases, of its one-pound butter blocks from shelves. The recalled butter was packed in white paperboard cases, each containing 36 one-pound blocks.

The affected products carry the lot code 5064036503 and were shipped to 12 distribution centers across the United States and one in the Dominican Republic.

Why the Undeclared Milk Is a Serious Concern

Milk is one of the nine major food allergens identified by the FDA, alongside eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans, and sesame. The FDA mandates clear labeling of such allergens because exposure, even in small amounts, can cause a range of reactions, from mild discomfort to life-threatening symptoms.

Food-related allergic reactions may include hives, facial swelling, vomiting, coughing, and skin irritation. More severe responses can result in anaphylaxis, a rapid-onset, whole-body allergic reaction that may lead to shock and, in extreme cases, death.

According to the Mayo Clinic, anaphylaxis occurs when the immune system floods the body with chemicals in response to an allergen. This can cause a sudden drop in blood pressure, narrowing of the airways, and potential organ failure if not treated immediately.

FDA Reiterates Importance of Allergen Labeling

In light of the recall, the FDA has emphasized the importance of allergen labeling and said it continues to enforce regulations requiring companies to clearly list all ingredients and potential allergens on packaging.

“More specific labeling requirements exist for foods that can cause allergies or other hypersensitivity reactions,” the agency stated. “These rules are designed to prevent accidental consumption of allergens and to protect consumers with dietary restrictions.”

The FDA also advised that anyone who experiences symptoms of an allergic reaction after consuming the recalled butter should “stop eating the food immediately, evaluate the need to use emergency medication (such as epinephrine), and seek medical attention.”

Company Yet to Comment

As of August 2, Bunge North America has not issued an updated public statement in response to the FDA’s reclassification and did not respond to a request for comment.

Food Safety Under Scrutiny Amid Other Recent Recalls

This butter recall follows a string of other high-profile food safety incidents this year. In recent weeks, more than 110,000 cases of popular chocolate ice cream bars were recalled across 23 states. Target-branded baby food was also pulled from shelves for containing “elevated levels of lead.”

Not forever, but what if you could press pause on Alzheimer’s just long enough to enjoy a few more good years? That is the tantalising promise behind a new drug called lecanemab, hailed as a game-changer in the fight against dementia.

The drug has already been licensed for use in the UK after trials showed it could slow the pace of decline in people with early-stage Alzheimer’s. But new long-term findings are turning cautious hope into something stronger: patients who stayed on lecanemab for four years experienced a noticeable delay in the disease's progression. Some even showed no decline at all.

How It Works

In the initial 18-month trial, the drug delayed Alzheimer’s progression by just under six months. That might not sound like much, but it’s the long game that matters here. Among 478 patients who remained on the drug for four years, the average delay before their disease advanced to the next stage stretched to almost 11 months.

Even more striking: 69 per cent of those with low levels of tau saw no decline at all over the four years. And over half in that same group actually improved their cognitive scores.

A Slow Slide Instead of a Steep Drop

Typically, people with mild Alzheimer’s see their scores on memory and function tests worsen by one or two points each year. But for those taking lecanemab, the total decline across four years was just 1.75 points. That’s a major shift in the rhythm of the disease, changing it from a downhill tumble to a slow shuffle.

Professor Christopher Van Dyck, who led the study at Yale School of Medicine, puts it simply: “You will get worse over time, but it will take longer to get there.” That extra time could mean more independence, more connection with loved ones, and more living.

Why Early Treatment is Key

This makes a strong case for early diagnosis and intervention, which could shift the way we approach Alzheimer’s care. No longer is it just about managing symptoms; it’s about changing the trajectory of the disease.

Not a Cure, But a Clear Step Forward

Lecanemab isn’t a miracle cure. It doesn’t reverse Alzheimer’s, and it’s not suitable for all patients. But experts say it’s a major milestone. Reportedly, this is the first wave of disease-modifying treatments and there’s still plenty to understand.

Other Contenders in the Ring

Lecanemab isn’t the only drug showing promise. A similar treatment called donanemab was tested over a three-year period, though it was only administered for 18 months. Still, the results were encouraging: patients on the drug gained an extra six to 12 months before their disease progressed.

That might not sound earth-shattering, but in a condition where time is everything, even a few more months of clarity and connection can be priceless.

The research is still evolving, but the signs are encouraging. With continued trials, this could be the start of a new chapter in dementia treatment, one where patients and families have more time to prepare, more time to enjoy life, and more hope than ever before.